{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:47:59Z","timestamp":1792597679190,"version":"4.5.0"},"reference-count":10,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"abstract":"<jats:p>This nonrandomized clinical trial assesses associations between psilocybin therapy and changes in systemic markers of inflammation and mitochondrial stress in people with Parkinson disease and mood dysfunction.<\/jats:p>","DOI":"10.1001\/jamapsychiatry.2026.2733","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:00:29Z","timestamp":1792594829000},"source":"Crossref","is-referenced-by-count":0,"title":["Psilocybin and Inflammatory and Mitochondrial Stress Markers in Parkinson Disease"],"prefix":"10.1001","author":[{"given":"Ellen R.","family":"Bradley","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco"},{"name":"Parkinson\u2019s Disease Research, Education, and Clinical Center, San Francisco Veterans Affairs Medical Center, San Franciso, California"},{"name":"Mental Health Service, San Francisco Veterans Affairs Medical Center, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parker","family":"Kelley","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Translational Psychedelic Research Program, Weill Institute for Neurosciences, University of California, San Francisco"},{"name":"Mental Health Service, San Francisco Veterans Affairs Medical Center, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"Szigeti","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Translational Psychedelic Research Program, Weill Institute for Neurosciences, University of California, San Francisco"},{"name":"Centre for Psychedelic Research, Imperial College London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Nishimi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Translational Psychedelic Research Program, Weill Institute for Neurosciences, University of California, San Francisco"},{"name":"Mental Health Service, San Francisco Veterans Affairs Medical Center, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Picard","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Division of Behavioral Medicine, Columbia University Irving Medical Center, New York, New York"},{"name":"Department of Neurology, H. Houston Merritt Center for Neuromuscular and Mitochondrial Disorders, Columbia University Irving Medical Center, New York, New York"},{"name":"New York State Psychiatric Institute, New York"},{"name":"Robert N Butler Columbia Aging Center, Mailman School of Public Health, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Translational Psychedelic Research Program, Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisele","family":"Fernandes-Osterhold","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Translational Psychedelic Research Program, Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill L.","family":"Ostrem","sequence":"additional","affiliation":[{"name":"Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M.","family":"Tanner","sequence":"additional","affiliation":[{"name":"Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Ludwig","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Translational Psychedelic Research Program, Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katiah","family":"Llerena","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Translational Psychedelic Research Program, Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick R.","family":"Finley","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of California, San Francisco"},{"name":"Women\u2019s Health Center, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Busby","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Translational Psychedelic Research Program, Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"McKernan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Translational Psychedelic Research Program, Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline Marie","family":"Pantoni","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Translational Psychedelic Research Program, Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Penn","sequence":"additional","affiliation":[{"name":"School of Nursing, University of California, San Francisco"},{"name":"Salma Health, Laguna Hills, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliss C. C.","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Translational Psychedelic Research Program, Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Rafael Pantoja","family":"Zuzuarregui","sequence":"additional","affiliation":[{"name":"Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Woolley","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Translational Psychedelic Research Program, Weill Institute for Neurosciences, University of California, San Francisco"},{"name":"Mental Health Service, San Francisco Veterans Affairs Medical Center, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoife","family":"O\u2019Donovan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Translational Psychedelic Research Program, Weill Institute for Neurosciences, University of California, San Francisco"},{"name":"Mental Health Service, San Francisco Veterans Affairs Medical Center, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"issue":"8","key":"yld260014r1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41386-025-02097-0","article-title":"Psilocybin therapy for mood dysfunction in Parkinson\u2019s disease: an open-label pilot trial.","volume":"50","author":"Bradley","year":"2025","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"yld260014r2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41531-023-00449-5","article-title":"A systematic review and meta-analysis of inflammatory biomarkers in Parkinson\u2019s disease.","volume":"9","author":"Qu","year":"2023","journal-title":"Npj Park Dis"},{"issue":"7","key":"yld260014r3","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1177\/02698811231164707","article-title":"Effects of serotonergic psychedelics on mitochondria: transdiagnostic implications for mitochondria-related pathologies.","volume":"37","author":"Fissler","year":"2023","journal-title":"J Psychopharmacol"},{"issue":"14","key":"yld260014r4","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1111\/bph.70138","article-title":"Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?","volume":"183","author":"Qureshi","year":"2026","journal-title":"Br J Pharmacol"},{"issue":"4","key":"yld260014r5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/da.22087","article-title":"Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder.","volume":"30","author":"O\u2019Donovan","year":"2013","journal-title":"Depress Anxiety"},{"issue":"7","key":"yld260014r6","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/acn3.51104","article-title":"Accuracy of FGF-21 and GDF-15 for the diagnosis of mitochondrial disorders: a meta-analysis.","volume":"7","author":"Lin","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"issue":"5","key":"yld260014r7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000214131","article-title":"What is the potential relevance of growth and differentiation factor-15 in neurologic disease?","volume":"105","author":"Benarroch","year":"2025","journal-title":"Neurology"},{"issue":"2","key":"yld260014r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2024.e00501","article-title":"Intranasal administration of mesenchymal stem cells overexpressing FGF21 demonstrates therapeutic potential in experimental Parkinson\u2019s disease.","volume":"22","author":"Lin","year":"2025","journal-title":"Neurotherapeutics"},{"key":"yld260014r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2026.121837","article-title":"Circulating Growth Differentiation Factor-15 (GDF-15) levels in depressive disorders\u2014a systematic review and meta-analysis of the association between GDF-15 and depression in adult populations.","volume":"408","author":"Jones-Murphy","year":"2026","journal-title":"J Affect Disord"},{"key":"yld260014r10","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2026.1726636","article-title":"Association between baseline circulating FGF21 levels and depressive symptoms at follow up in older adults: evidence from the FRASNET cohort.","volume":"17","author":"Damanti","year":"2026","journal-title":"Front Psychiatry"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2855669\/jamapsychiatry_bradley_2026_ld_260014_1792072272.59567.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:00:30Z","timestamp":1792594830000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2855669"}},"subtitle":["A Nonrandomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":10,"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2026.2733","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,21]]}}}